Biopharmaceuticals

Contract Biomanufacturing Services Global Market - Forecast to 2028

Retrieved on: 
Monday, September 28, 2020
Articles, Life sciences, Biotechnology, Pharmaceutical industry, Biomanufacturing, Biopharmaceuticals, Food industry, Compound annual growth rate

Contract manufacturing organizations, particularly for R&D and clinical trials, are making product manufacturing process more efficient and often less costly.

Key Points: 
  • Contract manufacturing organizations, particularly for R&D and clinical trials, are making product manufacturing process more efficient and often less costly.
  • The biologics contract manufacturing services global market is expected to reach $57.1 billion by 2028 growing at a low teen CAGR from 2020 to 2028.
  • The contract biomanufacturing global market is dominated by North American region which commanded the largest revenue in 2020 and is expected to grow at a low teen CAGR during the forecasted period according to estimation.
  • Asia-Pacific region is the fastest growing region in the contract biomanufacturing global market in 2020 and is expected to grow at high teen CAGR during the forecasted period.

Global Companion Animal Specialty Drugs Market (2020 to 2024) - Featuring Bayer, Henry Schein & Virbac Group Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 22, 2020
Pharmaceutical, Health, Veterinary, Life sciences, Articles, Biotechnology, Pharmaceutical industry, Biopharmaceuticals, Specialty drugs in the United States, Marketplace

The "Global Companion Animal Specialty Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Companion Animal Specialty Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The companion animal specialty drugs market is poised to grow by $ 2.29 billion during 2020-2024 progressing at a CAGR of 5% during the forecast period.
  • The reports on companion animal specialty drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The companion animal specialty drugs market analysis includes product segment and geographic landscape.

BioLife Solutions to Acquire SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry

Retrieved on: 
Monday, September 21, 2020
Branches of biology, Biology, Articles, Biopharmaceuticals, Bioproduction, Gene therapy

SciSafe had 2019 unaudited revenue of $6 million and positive EBITDA and is anticipated to be accretive during 2021.

Key Points: 
  • SciSafe had 2019 unaudited revenue of $6 million and positive EBITDA and is anticipated to be accretive during 2021.
  • Mike Rice, Chief Executive Officer of BioLife Solutions, commented, "This acquisition enables BioLife to offer even more value to our cell and gene therapy customers through an established business with an excellent reputation, marquee customers and seasoned team.
  • BioLife intends to fully leverage its relationships with leading cell and gene therapy companies to drive sales of SciSafe's suite of biologic storage services.
  • BioLife Solutions is a leading supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services.

Debut Biotechnology Awarded $1M from Air Force Research Lab to Leverage Cell-Free Continuous Biomanufacturing in Aerospace Applications

Retrieved on: 
Tuesday, September 15, 2020
Articles, Life sciences, Biopharmaceuticals, Biomanufacturing, Biotechnology, Food industry, Pharmaceutical industry, Cision, Air Force Research Laboratory, Aerospace

SAN DIEGO, Sept. 15, 2020 /PRNewswire-PRWeb/ -- Debut Biotechnology , a UC-Irvine spinout advancing scalable cell-free biomanufacturing, today announced that it has been awarded $1M from the Air Force Research Lab's Biotechnology Grand Challenge.

Key Points: 
  • SAN DIEGO, Sept. 15, 2020 /PRNewswire-PRWeb/ -- Debut Biotechnology , a UC-Irvine spinout advancing scalable cell-free biomanufacturing, today announced that it has been awarded $1M from the Air Force Research Lab's Biotechnology Grand Challenge.
  • Debut Bio is the inaugural recipient of the award, which honors the company's proposal on biosynthesis of monomers for aerospace applications.
  • Debut Bio's platform will provide AFRL with the ability to effectively and efficiently biomanufacture specialty ingredients needed for aerospace applications.
  • "The Air Force Research Lab has a well-documented history in discovering and leveraging breakthrough technologies.

Global Bio-pharmaceutical Manufacturing Capacity and Production Report 2020: Comparison of Production by Biotherapeutic Developers and Contract Manufacturing Organizations

Retrieved on: 
Monday, September 14, 2020
Articles, Life sciences, Biopharmaceuticals, Biotechnology, Biomanufacturing, Food industry, Pharmaceutical industry, Manufacturing

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- The "17th Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 14, 2020 /PRNewswire/ -- The "17th Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production" report has been added to ResearchAndMarkets.com's offering.
  • The 2020 17th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production.
  • In-depth analysis and summary of the key survey findings, trends and implications for industry-wide biomanufacturing capacity and biotherapeutic production.
  • Comparison of production by biotherapeutic developers and contract manufacturing organizations.

BioLife Solutions Named one of the Top 100 Companies in Washington State

Retrieved on: 
Tuesday, August 25, 2020
Branches of biology, Biology, Articles, Biopharmaceuticals, Bioproduction, Genetic engineering, Gene therapy

Mike Rice, BioLife's CEO, remarked, "Its a great honor for BioLife to make this esteemed annual list of the best companies in Washington, now for the third time since 2013.

Key Points: 
  • Mike Rice, BioLife's CEO, remarked, "Its a great honor for BioLife to make this esteemed annual list of the best companies in Washington, now for the third time since 2013.
  • I'm really pleased that our team members feel valued and recognized for their work.
  • We have such a talented and dedicated team that consistently rises to and overcomes whatever challenges come our way.
  • BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools.

Therapure Biomanufacturing Signs Manufacturing Deal With VBI Vaccines for Coronavirus Vaccine Candidates

Retrieved on: 
Tuesday, August 18, 2020
Manufacturing, Other Health, Technology, Nanotechnology, Pharmaceutical, General Health, Infectious diseases, Other Technology, Other Manufacturing, Science, Biotechnology, Other Science, Health, Engineering, Research, Articles, Life sciences, Biopharmaceuticals, Biotechnology, Biomanufacturing, Food industry, Pharmaceutical industry, Therapure BioPharma Inc, COVID-19 vaccine

Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates.

Key Points: 
  • Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates.
  • Therapure Biomanufacturing is an integrated contract development and manufacturing organization (CDMO) focused on biologic and high value therapeutics that can provide new options for patient care.
  • Under this agreement, Therapure will be responsible for the biomanufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at the Therapure facility in Mississauga, Ontario.
  • Therapure Biomanufacturing is the award-winning contract development and manufacturing division of Therapure Biopharma Inc. offering integrated services for developing, manufacturing, purifying and packaging complex biological therapeutics and technologies.

Canadian Biotech JN Nova Pharma Inc. Partners with the Government of Canada to Develop Therapeutic Platform for COVID-19

Retrieved on: 
Friday, August 14, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Articles, Life sciences, Pharmaceutical industry, Biomanufacturing, Biopharmaceuticals, Biotechnology, Food industry

JN Nova Pharma and the NRCs team from the Human Health Therapeutics Research Centre are co-developing a platform therapeutic approach based on multi-functional fusion protein(s) to address complex manifestations of COVID-19.

Key Points: 
  • JN Nova Pharma and the NRCs team from the Human Health Therapeutics Research Centre are co-developing a platform therapeutic approach based on multi-functional fusion protein(s) to address complex manifestations of COVID-19.
  • JN Nova Pharma will be a development partner for therapeutic modalities arising from this project, enabling their accelerated translation through biomanufacturing and towards clinical trials.
  • JN Nova Pharma executives, Dr. John Gillard, and Dr. Nathan Yoganathan are both experienced biotech drug developers.
  • Dr. John Gillard, CEO of JN Nova, indicated that they anticipate launching the first trials in humans within the next year.

Samsung Biologics to add fourth plant with growing demands

Retrieved on: 
Tuesday, August 11, 2020
Articles, Life sciences, Industries, Pharmaceutical industry, Biotechnology, Samsung, Samsung Biologics, Biopharmaceuticals, Contract manufacturing organization, Manufacturing, Biomanufacturing

INCHEON, South Korea, Aug. 10, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today held an online press conference to announce its plans to break ground for a fourth plant within this year.

Key Points: 
  • INCHEON, South Korea, Aug. 10, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today held an online press conference to announce its plans to break ground for a fourth plant within this year.
  • This is part of its long-term strategy to maximize its operational efficiency and scale up its development and manufacturing capabilities in response to growing biomanufacturing demands.
  • Samsung Biologics is taking an innovative approach in the design strategy of its new plant: by incorporating the unique advantages from Plant 1, 2, and 3, it will offer multi-scale manufacturing services to support the diversifying needs of new and existing clients.
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.

BioLife Solutions to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020

Retrieved on: 
Thursday, July 30, 2020
Branches of biology, Biology, Life sciences, Biopharmaceuticals, Bioproduction, Genetic engineering, Conference call, Gene therapy

Management will provide an overview of the Company's financial results and a general business update.

Key Points: 
  • Management will provide an overview of the Company's financial results and a general business update.
  • To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings .
  • Alternatively, you may access the live conference call by dialing 1 (888) 517-2485 with the following Conference ID: 9675894.
  • BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools.